Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Genetic variations in a fourth gene linked to elevated leukaemia risk in Hispanic children

Researchers have identified genetic variations in a fourth gene that are associated with an increased risk of acute lymphoblastic leukaemia (ALL) in Hispanic children.

Their study has been published in the journal Blood.

The gene ERG is a transcription factor that is also mutated in the leukemic cells of some ALL patients.

In this study, researchers identified inherited genetic variations in ERG that contribute to ALL risk - primarily in Hispanic children.

These are germline variants carried in cells throughout the body, rather than the previously reported somatic mutations in cancer cells.

ALL is the most common childhood cancer and Hispanic children have the nation's highest incidence of the disease.

They are also less likely than other children with ALL to survive.

"The more we understand the biology behind these disparities, the more likely we are to develop more effective therapies for different patient populations or better methods to track and monitor disease risk," said corresponding author Jun J. Yang, Ph.D., an associate member of the Hematological Malignancies Program of the St. Jude Comprehensive Cancer Center and the Pharmaceutical Sciences Department.

Ancestry and ALL risk

The study was a collaboration with the Children's Oncology Group and one of the largest efforts yet focused on Hispanic patients with ALL.

Yang and his colleagues compared common genetic variations in 940 genetically defined Hispanic ALL patients enrolled in COG clinical trials and 681 individuals of similar backgrounds without an ALL diagnosis. 

Ethnicity was assigned based on gene variations representative of European, African and Native American ancestry.

Hispanic ethnicity was defined as having more than 10 percent Native American gene variations as well as having more Native American than African gene variations.

Researchers confirmed previous findings that high-risk genetic variations in ARID5B, GATA3 and PIP4K2A were more common in Hispanic children and were associated with an increased chance of developing ALL.

The investigators also identified high-risk variations in ERG that were associated with a 1.56-fold increased risk of ALL in Hispanic children.

The individual risk, however, remains low, Yang emphasised.

The risk was highest (doubled) for children with the highest percentage of Native American ancestry and lowest (13 percent) for children with the lowest percentage.

"This was surprising, because the leukaemia genes that researchers had discovered before remained consistent across ancestries," Yang stated. 

In contrast, investigators found no significant increased ALL risk in African-American children with the high-risk ERG variations and just a 12 percent elevated risk in children of European ancestry.

"We found the high-risk ERG variants were more common in Hispanic children, but also had a stronger effect in Hispanics," Yang said.

Additional research is needed to understand the mechanism involved, including possible unidentified environmental or other factors that may play a role.

ERG and ALL risk

The findings also suggest ERG is an important regulator of normal blood development since either somatic mutations or germline variations that disruption gene function have now been implicated in causing leukaemia.

The Hispanic ALL patients in this study rarely had both ERG germline and somatic variations at the same time and the variations themselves also did not overlap.

Source: St. Jude Children's Research Hospital

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation